Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System following the Company's recent FDA 510(k) clearance. The limited market release began in late 2025, with a planned full market release at the Society of Interventional Radiology conference in April 2026.

LIBERTY is described as the only FDA‑cleared, single‑use, remotely operated robotic system for peripheral endovascular procedures, aiming to improve navigation precision and reduce radiation and ergonomic strain.

Positive

• First Florida health system adoption — Tampa General Hospital adopted LIBERTY
• Regulatory milestone — FDA 510(k) clearance achieved
• Commercial rollout — Limited market release commenced late 2025, scaling planned
• Unique product position — Only FDA‑cleared single‑use, remotely operated system for peripheral endovascular procedures
• Full release timeline — Full market release planned at SIR April 2026

Negative

• Early-stage commercialization — Adoption currently limited to a single health system in Florida
• Limited market release — Commercial footprint remains small pending full release at SIR April 2026

News Market Reaction – MBOT

+23.90% 1.7x vol

66 alerts

+23.90% News Effect

+25.0% Peak in 24 hr 42 min

+$35M Valuation Impact

$180M Market Cap

1.7x Rel. Volume

On the day this news was published, MBOT gained 23.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.0% during that session. Our momentum scanner triggered 66 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $35M to the company's valuation, bringing the market cap to $180M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

US peripheral endovascular procedures: 2.5 million procedures annually Service area population: more than 6 million Counties served: 15 counties +5 more

8 metrics

US peripheral endovascular procedures 2.5 million procedures annually Size of U.S. market for peripheral endovascular procedures

Service area population more than 6 million Population across 15 counties served by Tampa General Hospital

Counties served 15 counties Tampa General Hospital service area in West Central Florida

National specialties ranking top 50 in six specialties Tampa General Hospital national ranking by U.S. News & World Report 2025-26

Ranking period 2025-26 U.S. News & World Report ranking timeframe cited for Tampa General

Limited market release start late 2025 Commencement of LIBERTY limited market release

Full market release timing April 2026 Planned full market release at SIR conference

Regulatory pathway FDA 510(k) clearance Clearance status for LIBERTY Endovascular Robotic System

Market Reality Check

Price: $2.56 Vol: Pre-news volume of 933,17...

low vol

$2.56 Last Close

Volume Pre-news volume of 933,176 shares is below the 20-day average of 2,549,903 (relative volume 0.37). low

Technical Shares at $2.05 were trading below the 200-day MA of $2.58, and about 56.1% under the 52-week high.

Peers on Argus

Sector peers showed mixed moves pre-news: AVR (+7.4%), STXS (+4.39%), KRMD (+1.2...

1 Up

Sector peers showed mixed moves pre-news: AVR (+7.4%), STXS (+4.39%), KRMD (+1.27%) versus INFU (-4.29%) and NYXH (-2.64%). Only INFU appeared on the momentum scanner, moving up 6.54% without related news, suggesting stock-specific rather than coordinated sector momentum.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Conference panel feature	Positive	+0.9%	CEO featured on robotics and AI panel showcasing LIBERTY system.
Feb 12	Conference highlight	Positive	+4.5%	LIBERTY highlighted at major endovascular therapy conference with FDA clearance noted.
Feb 05	Oncology conference demos	Positive	-6.9%	Hands-on LIBERTY demos at oncology meeting during limited market release.
Jan 12	Milestones and outlook	Positive	+1.9%	2025 LIBERTY progress and 2026 commercialization milestones outlined.
Nov 26	First hospital adoption	Positive	+21.8%	Emory named first hospital to adopt LIBERTY for patient care.

Pattern Detected

Recent LIBERTY-related visibility and adoption news has generally seen positive or mixed immediate price reactions, with one notable negative divergence.

Recent Company History

Over the last few months, Microbot has steadily built visibility and adoption for the LIBERTY system. In Nov 2025, Emory University Hospital became the first clinical adopter, coinciding with a 21.81% gain. A Jan 12, 2026 update highlighted 2025 milestones, including FDA 510(k) clearance and a planned full release in Q2 2026. Subsequent February conference-focused announcements produced smaller mixed moves, suggesting that concrete adoption milestones, like today’s Tampa General news, have historically drawn stronger market attention than conference exposure alone.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active S-3/A shelf filed on 2025-10-28, with effectiveness to occur under Section 8(a) of the Securities Act. The amendment primarily updates technical language and fee details, with listed registration-related expenses of $25,000.00 including an SEC fee of $404.02. The shelf has recorded 2 usage events via Form 424B3 on 2025-11-19, while overall capacity figures are not specified in the provided data.

Market Pulse Summary

The stock surged +23.9% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +23.9% in the session following this news. A strong positive reaction aligns with the pattern seen when Microbot secured earlier LIBERTY adoption milestones, such as Emory’s first-in-world use that preceded a 21.81% gain. The Tampa General adoption adds another high-profile academic center ahead of the planned full release in April 2026 into a 2.5 million-procedure U.S. market. Investors would still need to weigh dilution capacity under the active S-3/A and the risk that early enthusiasm could fade if adoption ramps slower than expected.

Key Terms

endovascular, 510(k) clearance, peripheral endovascular procedures, radiation safety, +4 more

8 terms

endovascular medical

"advanced robotic solutions in peripheral endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

510(k) clearance regulatory

"following the Company’s recent FDA 510(k) clearance"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

peripheral endovascular procedures medical

"advanced robotic solutions in peripheral endovascular procedures"

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

radiation safety medical

"addressing growing concerns around radiation safety and ergonomic strain"

Radiation safety is the set of practices, equipment, training and rules used to limit exposure to ionizing radiation so people and the environment stay protected—think of it like seatbelts and airbags for workplaces that use X-rays, radioactive materials or radiation-producing machines. Investors care because strong radiation safety affects regulatory approval, operating costs, liability and reputation; failures can lead to fines, shutdowns or costly fixes that change a business’s financial outlook.

interventional cardiology medical

"across multiple specialties, including interventional cardiology, electrophysiology"

Interventional cardiology is a medical specialty that treats heart and blood-vessel problems using thin tubes and small tools inserted through a blood vessel instead of open surgery — for example placing stents or inflating tiny balloons to open a clogged artery. Investors care because it drives demand for specialized devices, procedures and training, and therefore revenue growth, regulatory review and adoption rates matter much like a new car part that must prove safe, effective and widely used before sales scale.

electrophysiology medical

"multiple specialties, including interventional cardiology, electrophysiology, and interventional radiology"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

interventional radiology medical

"including interventional cardiology, electrophysiology, and interventional radiology"

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

limited market release financial

"Sales Team is making further progress during the limited market release"

A limited market release is a staged launch of a product or service into a small group of customers, a specific region, or select sales channels before a full nationwide or global rollout. For investors it signals an early test of demand, production and distribution systems—like a pilot episode or a test drive—providing advance evidence about revenue potential, customer acceptance and the risks or costs of scaling up.

AI-generated analysis. Not financial advice.

Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced Robotics

HINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company’s recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance momentum for LIBERTY and highlights growing institutional readiness for advanced robotic solutions in peripheral endovascular procedures. The U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a significant and expanding clinical and commercial opportunity.

“As the first health system in Florida to adopt LIBERTY, we are advancing our commitment to leading-edge technology that has the potential to meaningfully transform how care is delivered,” said Dr. Jean Bismuth, Division Chief of Vascular Surgery for University of South Florida Morsani College of Medicine and Medical Director, TGH Heart & Vascular Institute. “LIBERTY brings sophisticated robotic capabilities to the endovascular space, allowing us to extend advanced innovation directly to our patients. It also has the potential to protect the long-term health of our physicians by addressing growing concerns around radiation safety and ergonomic strain. Within a collaborative model at TGH, we believe it is imperative that robotics ultimately be adopted as a programmatic platform across multiple specialties, including interventional cardiology, electrophysiology, and interventional radiology. This effort will initially be led within the Division of Vascular Surgery by Dr. Charles Briggs, who has emphasized that endovascular robotics has the potential to level the playing field and significantly enhance our ability to navigate increasingly complex anatomy.”

“Tampa General Hospital’s strong culture of innovation and clinical leadership makes them an ideal partner as the first health system in Florida to adopt LIBERTY,” said Harel Gadot, CEO, President & Chairman. “We believe that this serves as a powerful endorsement of LIBERTY’s differentiated value and market relevance. Additionally, Microbot’s Sales Team is making further progress during the limited market release, with engagement across additional hospitals, and early plans are underway to scale our commercial footprint ahead of the full market release at the Society of Interventional Radiology (SIR) conference this April.”

Tampa General is a nationally ranked research and academic medical center affiliated with the University of South Florida and one of the region's only university-level academic medical centers. Tampa General Hospital is a private not-for-profit hospital and one of the most comprehensive medical facilities in West Central Florida serving 15 counties with a population of more than 6 million. Consistently recognized for providing world-class care, Tampa General Hospital is ranked as the #1 hospital in Tampa Bay by U.S. News & World Report for 2025-26 and is nationally ranked among the top 50 hospitals in the nation in six specialties.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What did Microbot Medical (MBOT) announce about Tampa General Hospital on February 24, 2026?

Tampa General Hospital became the first health system in Florida to adopt LIBERTY. According to the company, this follows the recent FDA 510(k) clearance and marks early post‑clearance adoption during the limited market release.

Is LIBERTY FDA cleared and what makes it unique for MBOT (MBOT)?

Yes — LIBERTY received FDA 510(k) clearance and is single‑use and remotely operated. According to the company, it is the only FDA‑cleared single‑use robotic system for peripheral endovascular procedures.

When will Microbot Medical (MBOT) conduct the full market release of LIBERTY?

The company plans a full market release at the Society of Interventional Radiology conference in April 2026. According to the company, this event will be used to showcase LIBERTY and expand commercial adoption.

What clinical or operational benefits does LIBERTY claim to offer patients and physicians?

LIBERTY aims to enable precise vascular navigation while reducing radiation exposure and ergonomic strain. According to the company, the system is designed to protect physician health and extend advanced care to patients.

What is the current commercial status of LIBERTY after the late 2025 limited market release?

LIBERTY is in a limited market release with early hospital engagements and sales activity. According to the company, the sales team reports additional hospital engagement ahead of the planned full release at SIR April 2026.